about
Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cellsThe SIB Swiss Institute of Bioinformatics' resources: focus on curated databasesPancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathwayClinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupThe consensus molecular subtypes of colorectal cancerA Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis.Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.HES6 enhances the motility of alveolar rhabdomyosarcoma cells.Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells.BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas.Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.Genomic copy number and expression patterns in testicular germ cell tumours.Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumorsInconvenience of convenience cohorts--letter.Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia.Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours.PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse.MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical BehaviorActivation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcomaAllelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11Sex chromosome anomalies in pancreatic endocrine tumorsRole of disease-causing genes in sporadic pancreatic endocrine tumors:MEN1andVHLImmunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levelsAdditional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation.Thrombosis in patients with heterozygous and homozygous factor XII deficiency is not explained by the associated presence of factor V Leiden
P50
Q24632284-16766C8C-DCDA-4B1E-8595-7A74D10F2E5BQ27968301-5E1C1C95-4686-44EF-A5AB-C70AB7BF37F1Q34887795-AC342C74-8CA8-4D64-980C-6BEA56E034B1Q36175120-70B452E8-5F0B-4D29-9CE8-4F8BFEEE467AQ36258187-ABD87F29-CCBE-4601-AB2A-5BB35BDA6A7DQ36714160-851BFA63-5B74-41A1-8DBB-2EBA716FD8E9Q36903863-BB272E50-27A5-4DCA-95BD-732FA2043848Q37199465-4003AA7A-E70B-4984-AC47-A82A6A9FF529Q37257158-E6540EE5-352A-45B4-BDA6-C1D94A516712Q38337872-71A88C7C-B8E0-4BED-BCE4-E757C06CBA0AQ38350940-171539CF-E892-40CD-9B74-66C64C99B958Q38688601-F3E6A040-C5FE-4BCF-A306-F2DFA5ACD188Q39277802-0D4BDA2D-FDD7-4D82-9CD6-2B736EC624A2Q39446630-515D1AD3-62FB-4D8B-9EB7-6305456AFEAEQ39490299-A250ECFC-A5A6-488D-903A-EC56AF110D40Q39646999-A9A372B5-9F53-4DDB-A202-65AAED33E5E1Q39760480-A769A673-1E74-4065-BC3F-8FA35969C308Q39767891-B51A155E-FFC5-438D-9523-890EF145D15FQ39880703-1A22AEE1-478B-4DBE-9AA3-FF8B64ACB8FFQ40039629-EEB2E87D-E53A-4EE3-88E6-07DE3CDDE14CQ42037016-97618B27-283F-4807-8D02-D4BE1E87EB62Q42321484-425B875F-156D-40CB-9611-1F6A9BA1565AQ44131623-468EC7EA-8548-4DA8-B8E7-F43A724F895BQ45885024-23A72D61-4F02-463C-A16A-34924C4E626DQ45938699-1053521C-73BE-4972-8932-1AD503A30DCAQ46315247-184D3CEC-6D99-4341-9A0D-22723D6F510FQ47975012-337A58F1-EB8A-4281-80DC-3269C2EB7F67Q48177867-F17EC6EC-FDEB-4B4F-8A24-AECA59AF1D89Q50939418-15C1755D-5C2C-48D6-B49E-68976248805DQ53029961-C3EC3290-33B5-4465-80FD-82F1A8D742B8Q54434638-5E904F30-D930-4336-AB6F-43770C7F0348Q54621692-CD1AE330-9674-47C4-BFE6-0C9B2BFEE12BQ57200299-5A519DB3-1E01-4E53-8050-90904D40E49CQ57243407-706BC59B-0E4B-4BAB-B697-CFF20A5A43F4Q57290025-A37958A4-89CD-4D91-9F4B-691B86651FB3Q57290104-53FB7C03-6CBA-4AA2-A901-ED57DAD6DA3AQ57290138-E530EF69-C173-486D-99D2-0DD2C7FA7BCDQ61595895-A71C25D0-D826-4220-9EBA-4C4F41160483Q63247711-EAB68B16-EAD9-4FA2-9741-F896E772E76FQ71671912-5C7678D9-A78F-4632-96F4-A67EC4D281D8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Edoardo Missiaglia
@ast
Edoardo Missiaglia
@en
Edoardo Missiaglia
@es
Edoardo Missiaglia
@nl
type
label
Edoardo Missiaglia
@ast
Edoardo Missiaglia
@en
Edoardo Missiaglia
@es
Edoardo Missiaglia
@nl
altLabel
edoardo missiaglia
@en
prefLabel
Edoardo Missiaglia
@ast
Edoardo Missiaglia
@en
Edoardo Missiaglia
@es
Edoardo Missiaglia
@nl
P106
P31
P496
0000-0001-9221-0117